Agilent Technologies, Inc. A
172.79
(0.05)
(0.03%)
as of 25 Sep
- Market cap
- $49.0B
- P/E
- 33.9×
Follow A
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Agilent Technologies, Inc. (A) Shares outstanding
Agilent Technologies, Inc.'s shares outstanding at the end of fiscal 2025 was $285.0M, unchanged from fiscal 2024. At the end of the quarter to 31 July 2026 it was $283.0M. Over the past ten years it has ranged from $285.0M (fiscal 2025) to $335.0M (fiscal 2015) — the current reading is the lowest in ten years. Agilent Technologies, Inc. ranks 6th of 52 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $285.0M | (2.06%) |
| FY2024 | $291.0M | (1.69%) |
| FY2023 | $296.0M | (1.33%) |
| FY2022 | $300.0M | (2.28%) |
| FY2021 | $307.0M | (1.60%) |
| FY2020 | $312.0M | (1.89%) |
| FY2019 | $318.0M | (2.15%) |
| FY2018 | $325.0M | (0.31%) |
| FY2017 | $326.0M | (0.91%) |
| FY2016 | $329.0M | (1.79%) |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jul 2026 | $283.0M | 0.00% |
| Apr 2026 | $283.0M | (0.35%) |
| Jan 2026 | $284.0M | (0.35%) |
| Oct 2025 | $285.0M | 0.00% |
| 43 more quarters | Free account |
Against its own ten years
Low $285.0M
High $335.0M
Ten-year median
$312.0M
Current reading's percentile
9
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| A Agilent Technologies, Inc. | $283.0M |
| IQV IQVIA Holdings Inc. compare | $167.3M |
| ILMN Illumina, Inc. compare | $153.0M |
| NTRA Natera, Inc. compare | $143.3M |
| GH Guardant Health, Inc. compare | $132.9M |
| DGX Quest Diagnostics Incorporated compare | $112.0M |
| WAT Waters Corporation compare | $98.2M |
| IDXX IDEXX Laboratories, Inc. compare | $79.3M |
| MTD Mettler-Toledo International, Inc. compare | $20.2M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on A
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement